Overview

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
GMI-1070 is a new drug that may reduce the stickiness of cells in the blood. The purpose of this study is to evaluate whether GMI-1070 can reduce the time it takes for pain to go away in patients with vaso-occlusive crisis (also known as a sickle cell pain crisis). The study will also collect information on the safety of GMI-1070, how much of the drug is in the blood and urine, and if there are any other effects when used in patients who are in the hospital for a sickle cell pain crisis.
Phase:
Phase 2
Details
Lead Sponsor:
GlycoMimetics Incorporated
Pfizer